ZYMETX INC
10QSB, EX-27.1, 2000-11-14
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: ZYMETX INC, 10QSB, 2000-11-14
Next: ZYMETX INC, DEF 14A, 2000-11-14



<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          JUN-30-2001
<PERIOD-START>                             JUL-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                         702,620
<SECURITIES>                                 1,483,001
<RECEIVABLES>                                   73,898
<ALLOWANCES>                                    12,357
<INVENTORY>                                  2,647,245
<CURRENT-ASSETS>                             4,804,614
<PP&E>                                       1,071,452
<DEPRECIATION>                                 501,568
<TOTAL-ASSETS>                               6,000,910
<CURRENT-LIABILITIES>                        1,050,270
<BONDS>                                        370,395
                                0
                                          0
<COMMON>                                         6,866
<OTHER-SE>                                   4,573,379
<TOTAL-LIABILITY-AND-EQUITY>                 6,000,910
<SALES>                                         64,780
<TOTAL-REVENUES>                                64,780
<CGS>                                           33,384
<TOTAL-COSTS>                                1,493,660
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               9,241
<INCOME-PRETAX>                            (1,422,088)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (1,422,088)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (1,422,088)
<EPS-BASIC>                                     (0.21)
<EPS-DILUTED>                                   (0.21)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission